This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pelton, S. I.
Right arrow Articles by Klein, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pelton, S. I.
Right arrow Articles by Klein, J. O.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 110 No. 4 October 2002, pp. 805-814

SPECIAL ARTICLE

The Future of Pneumococcal Conjugate Vaccines for Prevention of Pneumococcal Diseases in Infants and Children

Stephen I. Pelton, MD and Jerome O. Klein, MD

From the Department of Pediatrics, Boston University School of Medicine, and Department of Pediatrics, Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston, Massachusetts

--> Seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in February 2000. In June 2000, the Advisory Committee on Immunization Practices and the American Academy of Pediatrics recommended the universal administration of pneumococcal conjugate vaccine for all children 23 months of age and younger and for children 24 to 59 months of age who are at high risk for serious pneumococcal disease. Since then, >23 million doses have been administered in the United States. Postlicensure surveillance of invasive pneumococcal disease (IPD) in the United States from the Active Bacterial Core Surveillance program at the Centers for Disease Control and Prevention and the Northern California Kaiser Permanente Vaccine Study Center has reported a decline in IPD and in pneumococcal disease incidence as a result of vaccine serotypes, respectively. During this period, issues critical to the long-term success of PCV7 have become more relevant: Will PCV7 be as effective in groups of children who are at high risk for IPD as in healthy children? Will nonvaccine types replace vaccine serotypes in the nasopharynx and in disease? Why are the results of the clinical trials different for IPD and for acute otitis media? How many doses of PCV7 and what concentrations of antibody are necessary for protection? Will universal administration of PCV7 to children younger than 2 years reduce antimicrobial drug resistance and alter prescribing patterns of physicians for febrile infants? Have there been unanticipated adverse events or benefits observed? The purpose of this report is to review the current data available to address these questions and to identify gaps that will require additional knowledge to determine the ultimate value of pneumococcal conjugate vaccines in reducing the burden of pneumococcal disease in infants and children.

Key Words: pneumococcal disease • pneumococcal vaccine • conjugate vaccine • carriage • serotypes

Abbreviations: PCV, pneumococcal conjugate vaccine • IPD, invasive pneumococcal disease • NCKP, Northern California Kaiser Permanente • HIV, human immunodeficiency virus • NP, nasopharyngeal • PPV, pneumococcal polysaccharide vaccine • ELISA, enzyme-linked immunosorbent assay • OPA, opsonophagocytic activity • MnCC, meningococcal group C conjugate vaccine • Hib • Haemophilus influenzae type b • DTP, diphtheria-tetanus-pertussis

Received for publication Feb 1, 2002; Accepted May 6, 2002.




This article has been cited by other articles:


Home page
 PediatricsHome page
S. S. Huang, R. Platt, S. L. Rifas-Shiman, S. I. Pelton, D. Goldmann, and J. A. Finkelstein
Post-PCV7 Changes in Colonizing Pneumococcal Serotypes in 16 Massachusetts Communities, 2001 and 2004
Pediatrics, September 1, 2005; 116(3): e408 - e413.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
R. Dagan, D. Goldblatt, J. R. Maleckar, M. Yaich, and J. Eskola
Reduction of Antibody Response to an 11-Valent Pneumococcal Vaccine Coadministered with a Vaccine Containing Acellular Pertussis Components
Infect. Immun., September 1, 2004; 72(9): 5383 - 5391.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. A. Finkelstein, S. S. Huang, J. Daniel, S. L. Rifas-Shiman, K. Kleinman, D. Goldmann, S. I. Pelton, A. DeMaria, and R. Platt
Antibiotic-Resistant Streptococcus pneumoniae in the Heptavalent Pneumococcal Conjugate Vaccine Era: Predictors of Carriage in a Multicommunity Sample
Pediatrics, October 1, 2003; 112(4): 862 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
K. M. Mason, R. S. Munson Jr., and L. O. Bakaletz
Nontypeable Haemophilus influenzae Gene Expression Induced In Vivo in a Chinchilla Model of Otitis Media
Infect. Immun., June 1, 2003; 71(6): 3454 - 3462.
[Abstract] [Full Text] [PDF]